Health Condition 1: null- Osteoarthritis
Conditions
Interventions
Intervention1: Homoeopathic medicine: Any one of the following homoeopathic medicine i.e. Rhus tox., Bryonia alba, Causticum, Pulsatilla, Arnica, Calcarea carb., Sulphur, Calcarea flour based on indiv
Sponsors
Central Council for Research in Homoeopathy
Eligibility
Inclusion criteria
Inclusion criteria: Patients above the age of 50 years, presenting with knee pain and evidence of osteophytes in the knee radiograph
Exclusion criteria
Exclusion criteria: • Rheumatoid factor more than 1:40 titre • ESR more than 40mm/hour • Serum uric acid level >7 mg/dL in men or >6 mg/dL in women • Severe degeneration of knee joint with marked joint narrowing, varus, or valgus deformity of knee ( > 12°); evidenced by imaging or other evidences and requiring surgical intervention • Non-ambulant patients • Self-reported joint disorders (e.g. inflammatory joint disease, specific arthropathy, severe axis deviations or instabilities, joint or skin infections, joint prostheses of the lower limbs) other than OA • IA injections within 2 weeks prior to study entry • Cases with other systemic unevaluated or uncontrolled diseases like diabetes mellitus, hypertension, or other cardiovascular, renal, gastro-intestinal, endocrinal, gynecological diseases etc. or systemic infections affecting quality of life or on other treatment therapies • Psychiatric illness • Patients with any vital organ failure • Recent knee surgery within last 6 months • Cases with transplanted knees • History of homeopathic treatment for any chronic disease within last 6 months • Self-reported immune-compromised states • Alcohol and/or drug addiction or dependence • Cases with controlled/uncomplicated hypertension, diabetes mellitus, etc. will not be excluded. Patients on life-saving conventional drug therapies, e.g. anti-diabetics, anti-hypertensives, thyroid drugs etc. for co-morbidities under control, will be continued.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in pain, stiffness, limitation of movement on an identified scale Change in pain measured on identified scale (OARSI - OMERACT constant/intermittent pain measure)Timepoint: every 15 days till 2 months of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in requirement of NSAIDs during the course of treatment â?¢ Incidence of any adverse events/severe adverse events during the period of treatmentTimepoint: every 15 days till 2 months of treatment | — |
Countries
India
Contacts
Public ContactDr Anil Khurana
Central Council for Research in Homoeopathy
Outcome results
None listed